# Comparison of a non-weight-based vs weight-based dose titration protocol for intravenous unfractionated heparin

## Thomas Cameron, B.Sc. (Hon), PharmD; Doson Chua B.Sc. (Pharm), PharmD, ACPR; Stephen Shalansky B.Sc. (Pharm), PharmD, ACPR Edwin Tam B.Sc.(Pharm); Erica Wang, B.Sc.(Pharm), PharmD, ACPR

### Background

- Unfractionated heparin (UFH) for the treatment of acute coronary syndrome, valve surgery, and venous thromboembolism is dosed according to weight and partial thromboplastin time (PTT) with low target (PTT 50-70s) and standard target (PTT 60-90s) protocols.
- The UFH protocols at St. Paul's Hospital (SPH) changed in May 2019 with implementation of Cerner electronic medical record.
- Previous protocol: Weight-based initial dose and subsequent dose adjustments.
- Current protocol: Weight-based initial dose only

### Objectives

- **Primary objective:** To compare the effectiveness of a non-weight-based vs weight-based dose titration protocol for IV UFH
- **Secondary objective:** To assess the effectiveness of the non-weight-based lowtarget protocol compared to weight-based low-target protocol for IV UFH

#### Methods

- Design: Retrospective, observational, before-and-after study
- **Inclusion:** SPH cardiology and cardiac surgery wards, Jan 2015–Aug 2016 (weight-based) and Jan-Oct 2020 (non-weight-based), Age >18, on IV UFH for any indication; convenience sample
- **Exclusion:** Did not follow UFH protocol, antiphospholipid antibody syndrome, acute liver failure (ALT 3xULN), contraindications to heparin
- Primary outcomes: (1) Number of dosage adjustments required to reach therapeutic PTT. (2) % of patients within therapeutic PTT 24h after initiation
- Secondary outcome: For low target protocol: Proportion of patients therapeutic after the 1<sup>st</sup> PTT measurement (at 6h)
- Statistics: Descriptive statistics
- Continuous variables: Parametric and non-parametric data analyses by twosample t-test and Wilcoxon rank sum test, respectively.
- Categorical variables: p-values tested by chi-squared tests
- Multivariate analyses included age, sex, and weight
- Comparisons of outcomes based on Poisson regression models for count data, logistic regression models for binary data, and multinomial logistic regression models for ordinal data





Results						
Non-weight-based: 448 Records Screened	on-weight-based: → 257 Records excluding duplicates → n = 130 included					
Jan – Oct 2020						
	collected. 15 not administered. 11 elevated ALT)					
		·		,		
Weight-based:	→ 1291Records excluding duplicates → n = 137 included					
1521 Records Screene	el be					
Jan 2015 – Aug 2010	1154 Excluded (1016 not reviewed, 56 not per protocol, 45					
	<3 PTIS (	collected, 21 other, 16 ho	ot administered			
Figure 1: Flow Diag	ram					
Table 1. Recaline Characteristics						
	Total	Non-weight-based	Weight based			
	(n= 267)	(n = 130)	(n = 137)	p-value		
Age						
Mean <u>+</u> SD	65.6 <u>+</u> 14.0	66.2 <u>+</u> 13.4	65.1 <u>+</u> 14.5	0.531		
Sex: n (%)						
F	82 (30.7)	40 (30.8)	42 (30.7)	0.984		
Weight (kg)						
Mean <u>+</u> SD	82.8 <u>+</u> 20.5	82.6 <u>+</u> 21.6	83.0 <u>+</u> 19.5	0.874		
Indication: n (%)						
UA + NSTE-ACS	75 (28.1)	29 (22.3)	46 (33.6)			
STE-ACS	31 (11.6)	28 (21.5)	3 (2.2)			
Atrial Fibrillation	109 (40.8)	49 (37.7)	60 (43.8)			
Heart Valve	19 (7.1)	13 (10.0)	6 (4.4)			
Other	33 (12.4)	11 (8.5)	22 (16.1)			
Protocol: n (%)						
Low target	158 (59.2)	66 (50.8)	92 (67.2)			
Standard target	109 (40.8)	64 (49.2)	45 (32.8)			









#### **Table 2: Summary of Outcon**

#### **Primary Outcome 1:**

Total number of adjustments reach 1<sup>st</sup> therapeutic PTT: median (Q1, Q3)

**Primary Outcome 2:** Patients therapeutic at 24h: Yes

#### **Secondary Outcome 1:**

Among Low target patients, therapeutic at 1st PTT: n (%) Yes

No

Above 70s Below 50s

#### Table 3: Multivariate Analyses (Non-weight-based vs weight-based)

		p-value
Primary Outcome 1:	RR 1.23 (0.95, 1.58)	0.119
Total number of adjustments to reach 1 <sup>st</sup>		
therapeutic PTT		
Primary Outcome 2:	OR 0.18 (0.02, 1.60)	0.124
Patients therapeutic at 24h Modelling unfeasible with most patients meeting outcome		
Secondary Outcome 1:		
Among Low target patients, therapeutic at 1 <sup>st</sup> PTT	-	
Above vs In Target	OR 0.73 (0.33, 1.62)	0.439
Below vs In Target	OR 2.23 (1.00, 4.99)	0.051
Above vs Below	OR 0.33 (0.14, 0.78)	0.012

#### Discussion

- dosing to a fully weight-based protocol.
- groups and similar to previous studies.
- protocol effectiveness in our study.
- electronic order entry and charting

#### Conclusion

previous fully weight-based protocol



nes			
	Non-weight-based (n = 130)	Weight-based (n = 137)	p-value
sto	1 (0 , 2)	1 (0,1)	0.483
n (%)			
	125 (96.1)	136 (99.3)	0.086
)	n = 66	n = 92	
)	25 (37.9)	41 (44.6)	0.033
	41 (62.1)	51 (55.4)	
	16 (24.2)	33 (35.9)	
	25 (37.9)	18 (19.5)	

Our study is the first to compare a UFH protocol using only weight-based initial

Both protocols resulted in high proportion of therapeutic PTTs at 24h (>96%), with median number of dose adjustments to 1<sup>st</sup> therapeutic PTT of 1 in both

The results suggest only weight-based initial dosing may be important for achieving therapeutic PTT. Weight-based dose adjustments did not impact

Our data suggest lower initial dosing in the non-weight-based low target protocol resulted in more subtherapeutic measurements at 1<sup>st</sup> PTT

Limitations of the study: non-randomized study design, change from paper to

This study suggests the current UFH protocol using only weight-based initial dosing is effective at achieving therapeutic PTT by 24h and similar to the